PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010079079) PDGF-Rβ BINDERS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS:

1. A PDGF-Rβ imaging agent comprising the polypeptide of any of SEQ. ID Nos 1, 2, 3, 4, 5, 6, 7, 8, 9 or a conservative variant thereof labeled with a signal generator, wherein the polypeptide binds specifically to PDGFR-β.

2. The imaging agent of claim 1, wherein polypeptide has a binding affinity of at least 10 nM to PDGFR-β expressed by A772 cells, U87 cells or M231 cells.

3. The imaging agent of any one of claim 1 or claim 2, wherein the polypeptide comprises at least two amino acid sequences selected from SEQ. ID NOs. 1, 2, 3, 4, 5, 6, 7, 8, 9 to form a multivalent polypeptide.

4. The imaging agent of any one of claims 1 to 3, wherein the multivalent polypeptide includes two repeated amino acid sequences have greater than 90% sequence identity to produce a divalent homogenous polypeptide.

5. The imaging agent of any one of claims 1 to 4, wherein the signal generator comprises a paramagnetic label, a radionuclide, or a fluorophore.

6. The imaging agent of claim 5, wherein the signal generator is an radionuclide and is selected from fluorine, iodine, technetium, gallium, or gadolinium.

7. The imaging agent of claim 6, wherein the fluorine comprises 18τ F,

8. The imaging agent of claim 6, wherein the 18F is attached to the polypeptide via an aminoxy linker.

9. The imaging agent of claim 6, wherein the 18F is attached to the polypeptide via an aminoxy linker at the N-terminus of the polypeptide.

10. The imaging agent of claim 6, wherein the iodine comprises 123I.

11. The imaging agent of claim 10, wherein the 123I is attached to the polypeptide via an aminoxy linker.

12. The imaging agent of claim 10, wherein the 123I is attached to the polypeptide via an aminoxy linker at the N-terminus of the polypeptide.

13. The imaging agent of claim 10, wherein the technetium comprises 99mTc.

14. The imaging agent of claim 13, wherein the 99mTc is attached to the polypeptide via a diaminedioxime chelator.

15. The imaging agent of claim 14, wherein the diaminedioxime chelator comprises cPn216.

16. The imaging agent of claim 14, wherein the 99mTc is attached to the polypeptide via a diaminedioxime chelator at the N-terminus of the polypeptide.

17. The imaging agent of claim 5, wherein the signal generator is a paramagnetic label selected from 157Gd, 55Mn, 162Dy, 52Cr, and 56Fe. 18. The imaging agent of claim 17, wherein the paramagnetic label is attached to the polypeptide via a chelator selected from NOTA, DOTA, DTPA.

19. The imaging agent of claim 6, wherein the radionuclide is comprised of Gd-153 or Ga-67, Co-55, Co-57, Cu-64, Cu-67, Zr-89, Y-86.

20. The imaging agent of claim 19, wherein the radionuclide label is attached to the polypeptide via a chelator selected from NOTA, DOTA, DTPA.

2 L A method of imaging a PDGF-Rβ-associated disease condition in a mammal comprising introducing into the mammal an polypeptide of any of SEQ. ID Nos 1, 2, 3, 4, 5, 6, 7, 8, 9 or a conservative variant thereof labeled with a signal generator, wherein the polypeptide binds specifically to PDGFR-β, permitting the agent to migrate to the disease tissue, imaging the diseased tissue using and, optionally, managing the disease condition.

22. The method of claim 21 , wherein the mammal is a human.

23. The method of claim 21, wherein the PDGF-Rβ-associated disease condition is liver fibrosis, cirrhosis, or abnormal liver function or a combination thereof.

24. The method of claim 21, wherein the imaging method is selected from PET, SPECT, MRI, radioimaging, and optical imaging.

25. The method of claim 21, further comprising treating the mammal before, after, or before and after imaging the imaging step, and using the results to manage the disease condition.

26. The method of claim 21 , wherein the agent is dispersed in a pharmaceutically acceptable solution with a pH of about 6 to about 8.